Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma.
Saponaro C, Vagheggini A, Scarpi E, Centonze M, Catacchio I, Popescu O, Pastena MI, Giotta F, Silvestris N, Mangia A. Saponaro C, et al. Among authors: giotta f. J Exp Clin Cancer Res. 2018 May 2;37(1):96. doi: 10.1186/s13046-018-0766-7. J Exp Clin Cancer Res. 2018. PMID: 29716631 Free PMC article.
Nuclear NHERF1 expression as a prognostic marker in breast cancer.
Paradiso A, Scarpi E, Malfettone A, Addati T, Giotta F, Simone G, Amadori D, Mangia A. Paradiso A, et al. Among authors: giotta f. Cell Death Dis. 2013 Nov 7;4(11):e904. doi: 10.1038/cddis.2013.439. Cell Death Dis. 2013. PMID: 24201803 Free PMC article.
A Gradient-Based Approach for Breast DCE-MRI Analysis.
Losurdo L, Basile TMA, Fanizzi A, Bellotti R, Bottigli U, Carbonara R, Dentamaro R, Diacono D, Didonna V, Lombardi A, Giotta F, Guaragnella C, Mangia A, Massafra R, Tamborra P, Tangaro S, La Forgia D. Losurdo L, et al. Among authors: giotta f. Biomed Res Int. 2018 May 16;2018:9032408. doi: 10.1155/2018/9032408. eCollection 2018. Biomed Res Int. 2018. PMID: 30140703 Free PMC article.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P. Pizzuti L, et al. Among authors: giotta f. Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7. Int J Cancer. 2020. PMID: 31330065 Free PMC article.
105 results